modelLenvatinib

Diagram of Lenvatinib

Extends from Pharmacolibrary.Drugs.ATC.L.L01EX08.

Information

name:Lenvatinib
ATC code:L01EX08
route:oral
compartments:2
dosage:24mg
volume of distribution:100L
clearance:7.0L/h
other parameters in model implementation

Lenvatinib is a multi-kinase inhibitor indicated for the treatment of certain types of cancer, including differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is an oral anticancer drug currently approved for use in several regions including the US and EU.

Pharmacokinetics

Population pharmacokinetic analysis in patients with advanced solid tumors, administered orally, typical adult population.

References

  1. Hu, Y, et al., & Zeng, Y (2022). Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data. Journal of clinical pharmacology 62(12) 1507–1517. DOI:10.1002/jcph.2103 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35689595

  2. Wei, Y, et al., & Zhang, X (2023). Effects of diet and gender on the pharmacokinetics of oral lenvatinib: A clinical trial in healthy Chinese participants. International journal of clinical pharmacology and therapeutics 61(11) 475–481. DOI:10.5414/CP204440 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37644876

  3. Gupta, A, et al., & Hussein, Z (2016). Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. British journal of clinical pharmacology 81(6) 1124–1133. DOI:10.1111/bcp.12907 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26879594

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)